Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT05882045

Obesity & weight · Phase 3 · Active, not recruiting

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

NCT05882045 · Sponsor: Eli Lilly and Company

What this trial means for you

This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Retatrutide, Placebo for obesity, cardiovascular diseases.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo — diagnosis required
What you'd takeRetatrutide, Placebo
Study length~2.9 years overall
Planned participants1,946
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Have a body mass index (BMI) ≥35.0 kilogram/square meter (kg/m²). * Have established cardiovascular (CV) disease with at least 1 of the following: * prior myocardial infarction * prior ischemic or hemorrhagic stroke, or * symptomatic peripheral arterial disease * Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight. Exclusion Criteria: * Have had acute myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure within 90 days prior to screening. * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * Have a prior or planned surgical treatment of obesity. * Have a change in body weight greater than 5 kg (11 pounds) within 90 days prior to screening. * Have Type 1 diabetes. * Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had pancreatitis.

Study sites by state

Arizona

  • Central Phoenix Medical Clinic — Phoenix

California

  • Valley Clinical Trials, Inc. — Covina
  • Neuro-Pain Medical Center — Fresno
  • Valley Research — Fresno
  • Collaborative Neuroscience Research, LLC — Los Alamitos
  • Velocity Clinical Research, Westlake — Los Angeles
  • Valley Clinical Trials, Inc. — Northridge
  • Velocity Clinical Research, Panorama City — Van Nuys

Connecticut

  • Chase Medical Research, LLC — Waterbury

Florida

  • Indago Research & Health Center, Inc — Hialeah
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare — Jacksonville
  • Clinical Neuroscience Solutions, Inc. — Orlando
  • Charter Research - Winter Park — Orlando
  • Progressive Medical Research — Port Orange

Hawaii

  • Pacific Diabetes & Endocrine Center — Honolulu

Idaho

  • Elite Clinical Trials — Blackfoot
  • Humphreys Diabetes Center — Boise

Illinois

  • Northwestern University — Chicago
  • Great Lakes Clinical Trials - Gurnee — Gurnee
  • Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative — Springfield

Indiana

  • Brengle Family Medicine — Indianapolis

Iowa

  • Iowa Diabetes and Endocrinology Research Center — West Des Moines

Kansas

  • Cotton O'Neil Diabetes & Endocrinology — Topeka

Massachusetts

  • MedVadis Research Corporation — Waltham

Missouri

  • StudyMetrix Research — City of Saint Peters

Nevada

  • Las Vegas Medical Research — Las Vegas
  • Palm Research Center Tenaya — Las Vegas

New Jersey

  • IMA Clinical Research Warren — Warren Township

New York

  • Weill Cornell Medical College — New York
  • Rochester Clinical Research, LLC — Rochester

North Carolina

  • Carteret Medical Group — Morehead City

Ohio

  • Cleveland Clinic — Cleveland

Pennsylvania

  • Altoona Center For Clinical Research — Duncansville
  • UPMC Montefiore University Hospital — Pittsburgh

South Carolina

  • Tribe Clinical Research, LLC — Greenville
  • Trial Management Associates — Myrtle Beach
  • Tribe Clinical Research - Spartanburg — Spartanburg

Texas

  • Texas Diabetes & Endocrinology, P.A. — Austin
  • Pinnacle Clinical Research — Austin
  • South Texas Clinical Research — Corpus Christi
  • Southern Endocrinology Associates — Mesquite
  • Texas Diabetes & Endocrinology, P.A. — Round Rock
  • Sleep Therapy Research Center — San Antonio
  • Consano Clinical Research, LLC — Shavano Park

Utah

  • Advanced Research Institute — Ogden

Washington

  • Rainier Clinical Research Center — Renton

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth